Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome
Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome
复制标题
DOI：
10.1002/ajh.10209
复制
发表时间：
2002-11-01
影响因子：
12.8
通讯作者：
Miller, K
中科院分区：
文献类型：
--
作者：
Chan, G;DiVenuti, G;Miller, K
在骨髓增生异常综合征(MDS)中，血小板减少是一个不良的预后指标。对有症状的血小板减少症患者的治疗选择有限。达那唑是一种减毒雄激素，在提高MDS患者的血小板计数方面可能有一定的疗效。我们回顾了33例接受达那唑治疗6周或更长时间的原发MDS患者。达那唑治疗6周后，平均血小板计数从42×10(9)/L升至60×10(9)/L(P<；0.015)，33例患者中有25例(76%)血小板计数升高。治疗12周后，平均血小板计数上升至67×10(9)/L(P<；0.005)，29例患者中有21例(72%)血小板计数升高。9名患者中有7名不再需要输注血小板，因为服用达那唑6周后出血停止。起效时间2~68个月，平均10个月。在所有法美英(FAB)亚型和所有国际预后评分系统(IPSS)得分中均可看到应答。治疗耐受性良好。丹那唑可能对血小板减少的MDS患者有效。(C)2002年Wiley-Liss，Inc.
Thrombocytopenia is a poor prognostic indicator in the myelodysplastic syndromes (MDS). Treatment options for patients with symptomatic thrombocytopenia are limited. Danazol, an attenuated androgen, may have some efficacy in increasing the platelet count of patients with MDS. We retrospectively reviewed 33 patients with primary MDS who were treated with danazol for 6 or more weeks. After 6 weeks on danazol, the mean platelet count increased from 42 x 10(9)/L to 60 x 10(9)/L (P < 0.015), and 25 out of 33 patients (76%) had an increase in their platelet counts. Following 12 weeks of treatment, the mean platelet count increased to 67 x 10(9)/L (P < 0.005), and 21 out of 29 patients (72%) had an increase in their platelet counts. Seven out of nine patients no longer required platelet transfusions because bleeding stopped after 6 weeks on danazol. Mean duration of response was 10 months (range 2-68 months). Responses were seen in all French-American-British (FAB) subtypes and in all International Prognostic Scoring System (IPSS) scores. Therapy was well tolerated. Danazol may be effective in MDS patients who are thrombocytopenic. (C) 2002 Wiley-Liss, Inc.